Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 291

Sort by

Sort Order Select

Journal Articles

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Vanthana Bharathi, Ian Bouligny, Emmanuel Almanza, Alex Bataller, Alexandre Bazinet, Wei-Ying Jen, Niranjan Khaire, Koji Sasaki, Danielle Hammond, Courtney DiNardo, Gautam Borthakur, Tapan Kadia, Naval Daver, Ghayas Issa, Musa Yilmaz, Kelly Chien, Guillermo Montalban-Bravo, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2025-5648

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Roberta S. Azevedo, Guillermo Garcia-Manero, Elias Jabbour, Danielle Hammond, Kelly Chien, Tapan Kadia, Steven Kornblau, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Hyunsoo Hwang, Xuelin Huang, Heather Schneider, Meghan Meyer, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2025-5645

Published: 2025

Journal Articles

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Ziyi Li, Kelly Chien, Yue Lyu, Koji Sasaki, Ian Bouligny, Yue Wei, Guillermo Montalban-Bravo, Sanam Loghavi, Alex Bataller, Uday Popat, Hagop Kantarjian, Alexandre Bazinet, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5644.

https://doi.org/10.1182/blood-2025-5644

Published: 2025

Journal Articles

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo, Kelly Chien, Danielle Hammond, Ian Bouligny, Jayastu Senapati, Koji Sasaki, Ghayas Issa, Nicholas Short, Tapan Kadia, Rashmi Kanagal-Shamanna, Sanam Loghavi, Guilin Tang, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2025-5641

Published: 2025

Journal Articles

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg, Richard Stone, Eric Padron, David Sallman, Curtis Lachowiez, Jonathan Abbas, Abhishek Mangaonkar, Mrinal Patnaik, Marissa Timothy, Alonzo Martinez, Ewelina Morawa, Brandon Turunen, Philip Vickers, Sergio Santillana

Blood (2025) 146 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2025-3874

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2025-3849

Published: 2025

Journal Articles

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Blood (2025) 146 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2025-3848

Published: 2025

Journal Articles

Synergistic apoptotic effect by the combination of clk inhibitor CTX-712 and BCL-2 inhibitor ABT-199 with or without azacytidine in AML and MDS

Hui Yang, Zhihong Fang, Yue Wei, Marcos Estecio, Guillermo Montalban-Bravo, Kelly Chien, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 3839.

https://doi.org/10.1182/blood-2025-3839

Published: 2025

Journal Articles

Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia

Yue Wei, Xiaoping Su, Ziyi Li, Sanam Loghavi, Hui Yang, Hong Zheng, Kirbie Linthicum, Vicky A. Appleman, Tiquella Hatten, Harry Huang, Jeffrey Raizer, Alex Parent, Neil Lineberry, Siddha Kasar, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 3832.

https://doi.org/10.1182/blood-2025-3832

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Jayastu Senapati, Elias Jabbour, Nitin Jain, Kelly Chien, Musa Yilmaz, Fadi Haddad, Guillermo Montalban-Bravo, Eitan Kugler, Wei-Ying Jen, Rita Khouri, Maro Ohanian, Rebecca Garris, Min Zhao, Guillermo Garcia-Manero, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2025-1573

Published: 2025

Journal Articles

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Hannah Goulart, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Caitlin Rausch, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Danielle Hammond, Mahesh Swaminathan, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2025-1566

Published: 2025

Journal Articles

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2025-1556

Published: 2025

Journal Articles

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Grace Park, Hagop Kantarjian, Nicholas Short, Nitin Jain, Farhad Ravandi, Kelly Chien, Jayastu Senapati, Fadi Haddad, Rita Khouri, Tapan Kadia, Naval Daver, Courtney DiNardo, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Naveen Pemmaraju, Rebecca Garris, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2025-1544

Published: 2025

Journal Articles

Dose intensive regimen of CK0804 tregs in myelofibrosis

Lucia Masarova, Mehrdad Abedi, Naveen Pemmaraju, Prithviraj Bose, Tapan Kadia, Jo Ishizawa, Guillermo Montalban-Bravo, Tara Sadeghi, Simrit Parmar, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5602.

https://doi.org/10.1182/blood-2025-5602

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Luspatercept response predictors in lower-risk myelodysplastic syndrome

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Synergistic apoptotic effect by the combination of clk inhibitor CTX-712 and BCL-2 inhibitor ABT-199 with or without azacytidine in AML and MDS

Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Dose intensive regimen of CK0804 tregs in myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only